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Abstract The use of antisense oligonucleotides (AOs) to induce
exon skipping leading to generation of an in-frame dystrophin
protein product could be of bene¢t in around 70% of Duchenne
muscular dystrophy patients. We describe the use of hyaluron-
idase enhanced electrotransfer to deliver uncomplexed 2P-O-
methyl modi¢ed phosphorothioate AO to adult dystrophic
mouse muscle, resulting in dystrophin expression in 20^30% of
¢bres in tibialis anterior muscle after a single injection.
Although expression was transient, many of the corrected ¢bres
initially showed levels of dystrophin expression well above the
20% of endogenous previously shown to be necessary for phe-
notypic correction of the dystrophic phenotype.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The use of antisense oligonucleotides (AOs) to redirect
splicing events has been proposed for the treatment of many
genetic diseases including beta-thalassemia [1], Huntingdon’s
[2], cystic ¢brosis [3], SMA [4] and Duchenne muscular dys-
trophy (DMD) [5^10]. The range of mutations in DMD pa-
tients has been described by several authors ([11] ; Leiden
Muscular Dystrophy database, http://www.dmd.nl/index.
html). It has been estimated that antisense methods to in-
duce exon skipping, thereby generating an in-frame trun-
cated but moderately functional dystrophin protein product,
could be of bene¢t in around 70% of DMD patients [8]. In the
dystrophin-de¢cient mdx mouse the point mutation in exon 23
of the dystrophin gene produces a premature termination co-
don [12]. The truncated protein product is rapidly degraded,
leading to absence of dystrophin. Redirected splicing between
exon 22 and exon 24 and thus exclusion of exon 23, has been
achieved in mdx cells in culture [13]. Recent improvements in
the design of AOs may increase the e⁄ciency of the correction
in this setting [6,14,15]. In other studies, redirected splicing in
patient lymphocytes or myoblast cultures has been demon-
strated [7^10,16].
Studies of manifesting female DMD carriers have suggested
that 20% of ¢bres in a muscle need to express near-normal
levels of dystrophin for maintenance of muscle function [17].
In transgenic mdx mice, expression of 20% of the endogenous
level of dystrophin at the membrane is required to prevent the
dystrophic phenotype [18,19]. Here we describe the applica-
tion of an optimised electrotransfer procedure to adult mdx
mice in vivo for delivery of uncomplexed AO directed to in-
duce skipping of exon 23, resulting in production of near-full-
length dystrophin in over 20% of myo¢bres after a single
injection.
2. Materials and methods
2.1. Oligonucleotides
The 2P-O-methyl phosphorothioate oligonucleotides (2OmeAOs)
were synthesised in-house on an Expedite 8909 Nucleic Acid Synthe-
sizer (Australian Neuromuscular Research Institute, University of
Western Australia). The AO, M23D(+2-18), used in this study (see
Fig. 1) was described by Mann et al. [14].
2.2. Electroporation procedure
In vivo experiments were carried out on male mdx mice, ranging in
age from 11 to 18 weeks old. Animals were housed in a disease-free
facility with food and water ad libitum. Prior to intramuscular injec-
tion, mice were anaesthetised with fentanyl/£uanisone and midazolam
(Hypnorm, Janssen Animal Health, High Wycombe, UK, and Hyp-
novel, Roche, Welwyn Garden City, UK, respectively). The tibialis
anterior muscles of anaesthetised animals were injected with hyaluron-
idase 2 h prior to injection and electrotransfer of the AO as previously
described [20]. Brie£y, 8 Wg AO was injected in normal saline in a ¢nal
volume of 25 Wl and an electrical ¢eld was applied to the muscle
immediately. The injection of AO and the electrotransfer was carried
out under iso£uorane inhalation anaesthesia. A voltage of 175 V/cm
was applied in ten 20 ms square-wave pulses at 1 Hz using a BTX
ECM 830 electroporator. Samples were then collected at various times
after the injection of AO. In all experiments, the contra-lateral TA
muscles were untreated so that the numbers of revertant ¢bres could
be assessed.
Mice were euthanised by cervical dislocation. TA muscles were
excised post mortem and either snap-frozen in liquid nitrogen for
analysis by Western blot or mounted on a cork block, embedded in
Cryo-M-Bed (Bright, Huntingdon, UK) and snap-frozen in liquid
nitrogen-cooled isopentane for histological analysis. To analyse trans-
fection e⁄ciency, 10 Wm cryostat sections were cut at a minimum of
10 evenly spaced levels throughout each muscle and lifted onto APES-
coated slides. All sections from each muscle were visually scanned and
the results reported in each case are from the section showing the
maximum number of dystrophin-positive ¢bres.
2.3. Immunostain and polyclonal antibodies
Sections were air-dried, endogenous biotin was blocked using an
avidin/biotin blocking kit following the manufacturer’s instructions
(Vector Laboratories, Peterborough, UK) and non-speci¢c binding
blocked for 30 min in 5% dried non-fat milk in PBS/0.05% Tween20.
Anti-dystrophin polyclonal DysC3750 [21] and polyclonal P6 sera
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(kind gift of Peter Strong; [22] were diluted in PBS/0.05% Tween20
plus 1% FCS. Bound antibody was detected using biotinylated anti-
rabbit 1:500 (Dako, Ely, UK) followed by ABC^HRP complex (Vec-
tor Laboratories, Peterborough, UK) and nickel-enhanced DAB. Sec-
tions were washed for 3U5 min between each step. Finally, slides were
washed in water, dehydrated through graded alcohols and mounted in
DPX (VWR International, Poole, UK).
2.4. RIPA preps and Western blot
Frozen TA muscle samples from injected and the contra-lateral
untreated muscles were solubilised and Western blotting was per-
formed as previously described [19,18]. Brie£y, RIPA bu¡er lysates
were solubilised in 10% SDS bu¡er and fractionated on a 6% polyac-
rylamide gel. Proteins were transferred to PVDF using a high ionic
strength transfer bu¡er modi¢ed from Nicholson et al. [23] by the
omission of methanol and addition of SDS to 0.05%. Equality of
protein transfer was assessed by amido black stain of the membrane.
Dy8/6C5, a kind gift from Louise Nicholson, Newcastle, was used at
1:100 dilution in TBST, followed by HRP-conjugated goat anti-
Fig. 1. Diagrammatic representation of the genomic sequences at
the boundary between exon 23 (uppercase letters in bold type) and
intron 23 (lowercase standard type) of the murine dystrophin gene.
The numbers above the sequence are used to designate the target
homology of the 2P-O-methyl modi¢ed AO M23D(+2^18). M=mu-
rine, 23= exon number, D=donor splice site, (+ ^) = annealing coor-
dinates, where +2 is last two exonic bases and ^18 represents the
¢rst 18 bases of intron 23 [14].
Fig. 2. Detection of dystrophin-positive ¢bres in wild-type (top row), mdx (second row), human minidystrophin transgenic mdx line AB2 (third
row) and in muscles following electrotransfer of AO (bottom row). Immunostaining of serial sections was carried out using either polyclonal
P6 at 1:800 dilution (left panels) or with polyclonal DysC3750 at a 1:2000 dilution (right panels). The scale bar indicates 25 Wm.
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mouse (Bio-Rad blotting grade secondary, Hertfordshire, UK) and
detection with ECL reagents (Amersham Biosciences, Chalfont St.
Giles, UK).
2.5. Statistics
Statistical analysis was carried out by one-way ANOVA followed
by multiple-paired comparison. Groups were considered to be signi¢-
cantly di¡erent when P6 0.05. Statistical tests were conducted using
SigmaStat from SPSS. Error bars shown in ¢gures and the values
given in the text are standard errors of the mean.
3. Results
Mdx mice were treated by electrotransfer of 8 Wg of AO and
samples collected at 1 week post-injection. To examine the
level of dystrophin expression induced by the AO, immuno-
staining was performed using a range of dilutions of
DysC3750. DysC3750 recognises the last 17 amino acids of
dystrophin [21] and will detect endogenous revertant ¢bres
[24] as well as dystrophin expression induced by the induced
exon skipping driven by the AO. The AO-injected mdx TA
muscles showed widespread distribution of dystrophin-posi-
tive ¢bres with a range of staining intensities. DysC3750
was also titred speci¢cally so that at a dilution of 1:2000 there
was no detectable staining in TA muscle from human mini-
dystrophin transgenic mdx line AB2 apart from intensely
staining revertant ¢bres. Line AB2 has approximately 20%
Fig. 3. Top: Dystrophin-positive ¢bres in a tibialis anterior muscle of an mdx mouse following electrotransfer of AO. Bottom: A low-power
image of a complete TA muscle section showing the distribution of dystrophin-expressing ¢bres across the whole area of the muscle. The scale
bars indicate 50 Wm (top panel) and 0.5 mm (bottom panel).
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of the wild-type level of dystrophin expression at the sarco-
lemmal membrane [18] and shows correction of the dystrophic
phenotype. A considerable proportion of the AO-induced dys-
trophin-positive ¢bres can still be detected even at this dilu-
tion of DysC3750, indicating that these ¢bres express well
above 20% of the wild-type dystrophin levels (Fig. 2). Fig. 3
indicates the large number of dystrophin-positive ¢bres ob-
tained and shows their widespread distribution across the
whole of the injected TA muscle after only a single injection
of AO.
The time course of dystrophin expression following AO
electrotransfer is indicated in Fig. 4. For each time point or
treatment six mdx male mice were injected with AO in one
TA. These mice were sampled at 2 weeks and 8 weeks post-
injection. In a further group of six mice the AO was injected
alone, with no other treatment of the muscle and no applica-
tion of electric pulses (direct injection only). The direct injec-
tion group was sampled at 2 weeks post-injection. In all cases
the contralateral muscle was untreated. There was a signi¢-
cant decrease in the number of detectable dystrophin-positive
¢bres between 2 weeks and 8 weeks post-injection of the AO.
The use of the hyaluronidase/electrotransfer protocol was sig-
ni¢cantly more e⁄cient than direct injection of AO in saline
without the application of electrotransfer (Fig. 4). The max-
imal transfection e⁄ciency obtained at 2 weeks post-injection
was 417 dystrophin-positive ¢bres in a transverse section after
a single injection, which corresponds to 28% of the muscle
¢bres.
Western blot analysis of dystrophin expression following
AO injection in individual TA muscles with electrotransfer
showed a low level of essentially full-length dystrophin (Fig.
5). The monoclonal antibody used on the blots was raised
against the last 17 amino acids of the 427 kDa muscle-speci¢c
isoform of dystrophin (which recognises both murine and hu-
man dystrophin) and will therefore only detect product that
includes these ¢nal amino acids. The induced skipping of exon
23 results in the loss only of 71 amino acids which would not
be resolved as a di¡erence in size to full-length dystrophin on
6% SDS acrylamide gels. No dystrophin was detected in ho-
mogenates of the uninjected contralateral control muscles.
4. Discussion
We have established a highly e⁄cient method of local gene
delivery to adult skeletal muscle using a combination of hy-
aluronidase pre-treatment and electrotransfer that allows us
to achieve transduction levels in mature muscle equal to or
surpassing those obtainable with viral vector systems [20]. We
have shown that this technique is also very e¡ective in the old
mdx mouse despite the presence of accumulating ¢brotic ma-
terial surrounding myo¢bres in the dystrophic muscle [21].
We show that, in contrast to the reported long half-life of
Fig. 4. Graph showing the number of dystrophin-positive ¢bres in muscle subjected to no treatment (uninjected, striped bars) or injected with
AO (solid bars). Muscles were sampled at 2 weeks or 8 weeks following hyaluronidase-enhanced electrotransfer or at 2 weeks post-injection of
the AO without any electrotransfer (direct injection only). Fibre numbers were determined using polyclonal DysC3750 at 1:500 dilution. Error
bars represent the standard error of the mean.
Fig. 5. Western blot of individual TA muscles from C57/Bl10 con-
trol (B10), uninjected contralateral control muscle (mdx) and the
mdx muscle 1 week post-electrotransfer of AO (mdx+oligo). The ar-
row indicates bands of full-length or almost full-length dystrophin
present in the wild-type and AO-treated muscles but not in the un-
treated control.
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the dystrophin protein in a transgenic analysis [25], the AO-
induced dystrophin expression is transient, possibly due both
to loss of the AO and to protein turnover. A phosphoro-
thioate backbone and 2P-O-methyl chemical modi¢cations
were combined to provide longer-term stability of the AO in
an in vivo situation particularly since the dystrophic pheno-
type of mdx muscle would increase the possibility of elevated
endonuclease activity in the injected muscle. Previous in vitro
studies have shown that scrambled oligonucleotides and AO
directed to splice site sequences at the acceptor splice site of
exon 23 are ine¡ective in inducing exon 23 skipping.
We clearly demonstrate that the hyaluronidase-enhanced
electrotransfer procedure can be used to e⁄ciently transfer
nucleic acids other than plasmids. In this case we show im-
proved transduction of single-stranded AOs containing some
chemical modi¢cations to enhance the biological persistence
of the AO. Further improvement in AO stability combined
with delivery methods applicable to multiple muscles (e.g.
vascular delivery [26,27]) would be needed to make this ap-
proach a therapeutic reality. This AO-mediated exon skipping
approach to the treatment of DMD is an attractive alternative
to gene replacement therapies, particularly given the estimated
number of patients for whom this treatment may be bene¢cial.
In addition, as naturally occurring revertant ¢bres are present
at low levels in the majority of DMD patients and other
tissue-speci¢c dystrophin isoforms may be present, the de
novo expression of almost full-length dystrophin is unlikely
to result in any adverse immune responses against dystrophin
[28].
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